Summary by Moomoo AI
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.